A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.
Advanced Solid Tumor
BIOLOGICAL: Adebrelimab|BIOLOGICAL: SHR-1802|DRUG: Carboplatin/Cisplatin|DRUG: Paclitaxel/Nab-Paclitaxel/Pemetrexed
Dose limiting toxicity (DLT), 3 weeks|Recommended phase II dose (RP2D), up to 2 months|ORR, Objective Response Rate, determined according to RECIST v1.1 criteria, up to 2 years
DOR, Duration of Response, determined according to RECIST v1.1 criteria, up to 2 years|DCR, Disease Control Rate, determined according to RECIST v1.1 criteria, up to 2 years|PFS assessed by investigator, Progression Free Survival, determined according to RECIST v1.1 criteria, up to 2 years|TTR, Time to Response，determined according to RECIST v1.1 criteria, up to 2 years|OS (overall survival), From date of treatment start to any cause death or last follow-up, up to 2 years|12-month OS rate, from the date of the first dose up to 2 years
The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.